Mark De Ridder
Mark De Ridder graduated at the medical school of the Vrije Universiteit Brussel (VUB, Belgium). He combined his training in radiotherapy and oncology at the UZ Brussels with a Doctoral Fellowship from the Research Foundation-Flanders (FWO) and defended his PhD “Hypoxic tumor cell radiosensitization through nitric oxide synthase: role of the NF kappa-B signaling pathway” in 2005. He was nominated Professor in radiotherapy and oncology at the VUB in 2008 and succeeded his mentor Professor Guy Storme as the Chair of the Radiotherapy Department of the UZ Brussels in 2010. His research group is specialized in radiobiology, clinical trials, and translational research and in the development of high-tech radiation techniques. They contributed “Innovations in image-guided radiotherapy” to Nature Reviews Cancer and are the first worldwide to clinically implement the VERO Stereotactic Body RadioTherapy (SBRT) system, in a research joint venture with the Hercules foundation of the Flemish government and Brainlab AG. Their ultimate goal is translating biological information and high-precision radiotherapy into patient-tailored radiotherapy. Mark contributed to the Lancet Oncology commission “Delivering affordable cancer care in high-income countries”. He is Vice-Chairman of the board of directors and Vice-President of the medical council of the UZ Brussels.
Biography Updated on 25 October 2012